

1 Article

2 A Fully Integrated *in vitro* Diagnostic Microsystem 3 for Pathogen Detection Developed Using a “3D 4 Extensible” Microfluidic Design Paradigm

5 Zhi Geng¹, Yin Gu^{1,2}, Shanglin Li^{1,2}, Baobao Lin¹, and Peng Liu^{1,*}

6 ¹ Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, 100084, China;
7 gengz15@mails.tsinghua.edu.cn (Z.G.); y-gu13@tsinghua.org.cn (Y.G.); li-sl14@tsinghua.org.cn (S.L.);
8 lbb17@mails.tsinghua.edu.cn (B.L.)

9 ² FengteBio Corporation, Beijing, 100079, China;

10 * Correspondence: pliu@tsinghua.edu.cn; Tel.: +86-10-6279-8732

11

12 **Abstract:** Microfluidics is facing critical challenges in the quest of miniaturizing, integrating, and
13 automating *in vitro* diagnostics, including the increasing complexity of assays, the gap between the
14 macroscale world and the microscale devices, and the diverse throughput demands in various
15 clinical settings. Here a “3D extensible” microfluidic design paradigm that consists of a set of basic
16 structures and unit operations was developed for constructing any application-specific assay. Four
17 basic structures- check valve (in), check valve (out), double-check valve (in and out), and on-off
18 valve, were designed to mimic basic acts in biochemical assays. By combining these structures
19 linearly, a series of unit operations can be readily formed. We then proposed a “3D extensible”
20 architecture to fulfill the needs of the function integration, the adaptive “world-to-chip” interface,
21 and the adjustable throughput in the X, Y, and Z directions, respectively. To verify this design
22 paradigm, we developed a fully integrated loop-mediated isothermal amplification microsystem
23 that can directly accept swab samples and detect *Chlamydia trachomatis* automatically with a
24 sensitivity one order higher than that of the conventional kit. This demonstration validated the
25 feasibility of using this paradigm to develop integrated and automated microsystems in a less risky
26 and more consistent manner.

27 **Keywords:** *in vitro* diagnostics; microfluidics; full integration; lab-on-a-chip; pathogen detection

28

29 1. Introduction

30 Since its inception, microfluidics has demonstrated a tremendous potential to revolutionize the
31 field of *in vitro* diagnostics (IVDs). Microfluidic IVD systems are believed to offer numerous
32 advantages, such as portability, low cost, automation, and “sample-to-answer” capability, which
33 could enable rapid, sensitive, and quantitative analyses of multiple targets by consuming minimal
34 amounts of samples [1,2]. Especially, these microfluidic systems should be able to play vital roles in
35 nucleic acid amplification tests (NATs) where the operation process is complicated and the
36 prevention of contamination is a critical concern [3,4]. However, so far it is still uncommon to see
37 microfluidic devices being routinely used in clinical diagnoses [5,6]. Why has this long-believed
38 potential of microfluidics not been turned into reality yet?

39 To advance the microfluidics, researchers often borrowed ideas from the microelectronic
40 industry, where the design and fabrication of electronic circuitries can be achieved by combining
41 validated basic elements and processes [7-9]. Similarly, instead of developing isolated microfluidic
42 systems, the implementation of a microfluidic platform, which comprises a combinable set of basic
43 unit operations, is a much easier and less risky approach to translate *in vitro* diagnostic assays to the

44 microchip format [9-11]. Indeed, in the last two decades, various microfluidic platforms have been
45 successfully proposed for the integration and miniaturization of biochemical assays. According to
46 the dominating liquid propulsion principles, the microfluidic platforms can be categorized to:
47 capillary [12,13], mechanical driven [14], liquid or air pressure driven [15], centrifugal [11,16],
48 electroosmotic [17], electrowetting [18], and acoustic systems [19]. Undoubtedly, these platforms
49 provide a full spectrum of tools for developing various microfluidic systems.

50 Unfortunately, when the IVD assays were miniaturized and integrated, some technical
51 challenges associated with the specific requirements of clinical diagnosis arose and may hurdle the
52 penetration of microfluidic systems into the IVD market [5]. The first challenge is the so-called
53 “world-to-chip” interface which includes two aspects: the reagent (sample) volume and the reagent
54 (sample) type [20]. In clinical diagnosis, the volume of the sample needs to be large enough to have
55 clinical relevance. For example, the accurate diagnosis of encephalitis requires a sensitivity down to
56 1 PFU/mL in cerebrospinal fluid [21]. As a result, a microfluidic device needs to handle at least 1 mL
57 of sample, which is usually thousands of times higher than the volume of a typical microreactor (less
58 than 1 μ L) [22,23]. One solution is to attach enlarged reservoirs or tubes on microdevices to
59 accommodate large-volume solutions [24,25]. However, these structures were only used as storage
60 compartments and more complicated manipulations of large-volume reagents, such as mixing, have
61 not been realized. Additionally, clinical samples may come in various forms: swabs, sputum, blood,
62 urine, feces, *etc.* Since these samples are often viscous, prone to forming bubbles, and full of particles,
63 the direct processing of raw samples was often excluded from an integrated microfluidic device
64 [26,27]. Second, while more and more *in vitro* diagnoses have been translated into microfluidic
65 formats, the integration of a complete bioassay into a single device remains as a formidable task that
66 requires many rounds of trials and failures [28]. Although the modular design methods, such as
67 Lego[®]-like [29,30] and plug-n-play [31] components, have been proposed, these technologies were
68 inherently developed for quickly testing new ideas in a prototype way instead of product
69 development [32]. Third, as the assays have become more and more complicated, the pursuit of
70 throughput has not been stopped. Although the microfluidics possesses the inherent advantage of
71 high throughput just like the microelectronics, it is not an easy task to simply array a microdevice
72 considering the complicated microstructures and the “world-to-chip” interfaces that the device may
73 have [28]. Furthermore, since an IVD system may be deployed to a variety of clinical settings, such
74 as central laboratories, physicians’ offices, and bedsides, ideally, this system should be able to provide
75 an adjustable throughput that can be adjusted according to the actual need at each run [6]. Overall,
76 the current available microfluidic platforms fall short of addressing these challenges encountered in
77 clinical diagnosis more or less and a more powerful design paradigm is highly desired.

78 Typically, these challenging issues faced by microfluidic systems are inevitable in NATs-based
79 pathogen detection. A desired IVD microsystem for pathogen detection is supposed to possess at
80 least the three following features. First, manual operations should be minimized in order to protect
81 operators from the infectious pathogen. This would set a high demand on the integration of the
82 system, especially on the integrated sample pre-processing where difficulties lies in the “world-to-
83 chip” interface. Wang *et al.* has developed a microsystem for rapid detection of respiratory viruses
84 based on loop-mediated isothermal amplification (LAMP) [33]. Since the chip could not directly
85 handle the throat swab, instead accepting the lysates from manual nucleic acid extraction, there might
86 be potential problems for non-expert users outside specialized laboratory. Second, the detection
87 should be performed immediately and cost efficiently, for which the adjustability in throughput
88 would be of critical importance in practical settings. Phaneuf *et al.* has developed a portable system
89 for diarrheal disease detection with integrated sample handling [34]. However, only one disk could
90 be operated on the instrument, and thereby it might be unfit in detecting multiple samples. Last but
91 not least, the microfluidic method should prove its advantages over the conventional method, in
92 improving the sensitivity or lowering the cost.


93 In the current study, a “3D extensible” microfluidic design paradigm was developed to address
94 the aforementioned critical issues in developing fully integrated IVD microsystems. Based on the
95 classical elastic film microvalves actuated by pneumatics [35,36], we designed four basic function

96 elements- check valve (in), check valve (out), double-check valve (in and out), and on-off valve, and
97 two structure elements- chamber and compartment, fabricated using a consistent tape-based
98 microfabrication technique. We proposed a “3D extensible” architecture to fulfill the needs of the
99 function integration, the adaptive “world-to-chip” interface, and the adjustable throughput in the X,
100 Y, and Z directions, respectively. To elucidate and verify this design paradigm, we developed a fully
101 integrated loop-mediated isothermal amplification (iLAMP) microsystem with “sample-in-answer-
102 out” capacity, adjustable throughput, and higher sensitivity compared with commercial kit. This
103 example validated the feasibility of using this universal design paradigm to develop fully integrated
104 and automated microfluidic systems in an easier, less risky, and more consistent manner.

105 2. Materials and Methods

106 2.1. Design paradigm of the “3D extensible” microfluidic systems

107 Similar to the digital logic gates (AND, OR, NOT, etc.) in a digital electronic circuit, the basic
108 function elements in a microfluidic platform should mimic the most fundamental acts in a
109 biochemical assay. As illustrated in Figure 1A-D, four basic acts in an assay were identified: adding
110 a solution to a tube, taking a solution from a tube, taking and then adding a solution, and
111 opening/closing a tube. These acts can be achieved by employing a series of derivative structures
112 modified from the classical elastic membrane valve in which an elastic membrane is sandwiched
113 between two chip layers [35,36]. As shown in the exploded views of Figure 1A-D, these sandwich
114 structures consist of a 3D block, a membrane, and a thin chip. The block contains a compartment with
115 a milliliter-scale volume, representing the macroscale section of the structure. The chip has microliter-
116 scale channels and chambers fabricated on the upper side, representing the microscale section. As
117 illustrated in Figure 1A, the act of “adding a solution to a tube” is realized using a check valve (in),
118 in which a hole punched through the membrane has a flush contact with the bottom of the block. A
119 pressure from the top compartment can bend the membrane to open the valve freely, but the reversed
120 direction is stopped by the bottom of the block. By applying a pressure from the compartment, the
121 solution stored in the compartment is driven into the microchannel on the chip, just like the act of
122 “adding a solution from a pipette to a tube”. Similarly, a check valve (out) is employed to achieve the
123 act of “taking a solution from a tube” (Figure 1B). The double check valve is the combination of these
124 two types of check valves for mimicking the act of “taking and then adding a solution” (Figure 1C).
125 Finally, the on-off valve, which is the classical pneumatic microvalve, is used to shut off a channel
126 connecting to a chamber (tube) in the chip, representing the closing or opening of a tube (Figure 1D).
127 To make the design schematic more explicit, four symbols were assigned to these basic structures.
128 The square in the symbol stands for the compartment in the block, the arrows indicate the flow
129 directions of the check valves, and the horizontal lines are the channels located on the upper side of
130 the chip.



131

132 **Figure 1.** The basic elements and the architecture of the "3D extensible" microfluidic design paradigm.

133 (A) A check valve (in), (B) a check valve (out), (C) a double check valve, and (D) an on-off valve, were
 134 designed as four basic elements. (E) A schematic replicating a biochemical assay can be drawn by
 135 sequentially linking the symbols of the basic elements. (F) The linear arrangement of the basic
 136 elements can produce a cassette-like device, which shares the consistent three-layer structure as the
 137 basic elements: a 3D block, a piece of membrane (DS tape), and a 2D chip. The design of the
 138 microdevice is extensible in three directions: in the X direction, the combination of basic elements can
 139 be customized to achieve different functions; in the Y direction, the 3D block functions as the "world-
 140 to-chip" interface for liquid storage, fluid control, and signal detection; in the Z direction, the cassette
 141 can be arrayed to achieve an adjustable throughput according to the need at each run.

142 With these basic elements in hand, a complicated biochemical operation comprising a series of
 143 basic acts can be converted into a schematic diagram by linking the symbols of the selected elements
 144 via microchannels, just like drawing a schematic of an electric circuit using the electric components
 145 from a component library. For example, as shown in Figure 1E, reagent A and B are sequentially
 146 added into a tube and mixed. After the lid is closed, the reaction begins. Following these steps, more
 147 operations can be conducted to manipulate the products of the reaction, and finally, all the wastes
 148 are collected in a waste tube. Each act in this process can be represented by a basic element described
 149 above and all the elements are linked sequentially by the microchannels. The implementation of the
 150 linear arrangement of elements in the schematic can produce a slim, cassette-like device, which
 151 consists of three parts: a 3D block, double-sided tape, and a 2D chip, as illustrated in Figure 1F. This
 152 double-sided tape (DS tape) with an acrylic foam base (4910 VHB, 3M, Maplewood, MN) was
 153 employed to bond the microdevice and to function as the elastic membrane in valves. In this cassette,
 154 the flow direction in the chip is defined as the X axle (the "function" direction), along which a series
 155 of basic elements are linked via the channels to perform a complete bioassay. The length of the chip
 156 along the X direction can be adjusted according to the integrated functions on the chip. In the vertical
 157 Y axle (the "interface" direction), the height of the block which functions as the "world-to-chip"
 158 interface can be adjusted according to the required volumes of the compartments in order to
 159 accommodate the samples and the reagents needed in the assays. All the control accesses are also
 160 applied to the device in the Y direction. Lastly, the cassette can be arrayed along the Z direction (the
 161 "throughput" direction) to achieve a higher throughput. The number of cassettes is adjustable to meet
 162 the throughput need of each run. A connection manifold can be pressed down to hold the device

163 array in place and to provide all the pneumatic connections and external controls to the devices. This
164 “3D extensible” device architecture can fulfill the specific demands of an IVD assay, including the
165 function, the “world-to-chip” interface, and the throughput, in a flexible way.

166 2.2. Fabrication of “3D extensible” microfluidic devices

167 The slim, cassette-like microdevice has three parts: a 3D block, a piece of patterned double-sided
168 adhesive tape, and a planar chip. Both the block and the chip were manufactured using the
169 conventional milling and drilling techniques. The non-adhesive patterning procedure of the DS tape
170 is illustrated in Figure S1. Briefly, a pattern designed with AutoCAD (Autodesk, San Rafael, CA) was
171 carved onto a piece of release paper (CY9970, Yichuang Electric, Suzhou, China) using a flatbed
172 cutting plotter (FC4500-50, Graphtec Corporation, Tokyo, Japan). Then, a piece of DS tape with its
173 own release paper peeled off was covered with the patterned release paper as masks from both sides.
174 Next, tris-HCl (pH=8.0) was pipetted onto the exposed surfaces of the tape and incubated at 37 °C for
175 30 min to remove the adhesiveness. After the holes in check valves were manually punched and the
176 masks were peeled off, the patterned DS tape was aligned to the block and the chip and pressed
177 together with fingers to drive out any residual gas in the bonding interfaces. The assembled
178 microdevice was kept at room temperature for at least 24 hours before use in order to let the tape-
179 bonding strength reach to its maximum. All the demo devices of unit operations were fabricated
180 following this general procedure.

181 In the fabrication of the iLAMP microdevice, a piece of glass filter paper (GF/D, Whatman, GE
182 Healthcare, Pittsburgh, PA) modified with chitosan (molecular weight: 2000, Sigma-Aldrich, St.
183 Louis, MO) was embedded in the chamber for DNA capture and “*in situ*” amplification. The
184 modification protocol of the glass filter paper can be found in our previous study [37]. Briefly, a piece
185 of glass filter paper (47 mm diameter) with a thickness of 2 mm was first activated with oxygen
186 plasma for 1 min, and then submerged in a chitosan solution (1% (w/v) in 1% acetic acid, pH 5.0)
187 followed by an overnight incubation on a tube roller. Then, the filter paper was washed with DI water
188 three times and dried completely at 50 °C in a vacuum drying oven. The trapezoid-shaped filter with
189 an area of 1 mm² was punched off with a customized mental puncher and directly released into the
190 end of the chamber on the chip. After that, a piece of adhesive PCR plate foil (AB0626, Thermo Fisher,
191 Waltham, MA) patterned using the cutting plotter was carefully aligned and attached onto the upper
192 side of the chip, covering the filter paper in the enclosed amplification chamber while leaving the
193 microchannels open. This covered chip was pressed hardly with a manual hydraulic press (15-1-HT,
194 GRIMCO, Paterson, NJ) before bonded with the block and the patterned DS tape.

195 2.3. Control and detection instrument

196 A control and detection instrument for the iLAMP microdevices was constructed with
197 pneumatics for fluid manipulation, electronics for temperature control, and optics for fluorescence
198 detection. Its core structure is shown in Figure S2. Up to eight microdevices can be put onto a Teflon
199 stage, on which six pieces of ITO (indium tin oxides) glass (Meijingyuan Glass Technology, Foshan,
200 China) were embedded side by side to form a heating zone with dimensions of 2.4×12 cm. The
201 temperature control of the ITO heater was accomplished through a
202 proportion/integrator/differentiator (PID) module, which used a thermocouple attached to the lower
203 side of the first ITO glass for signal feedback. The microdevices were hold in place by a custom-built
204 connection manifold, which contained an array of pneumatic ports connected to a pneumatic control
205 module. Within this module, two rotary vane pumps (G02-8, Gardner Denver Thomas,
206 Fürstentfeldbruck, Germany) were employed to provide pressure (5.9 psi) and vacuum (-5.3 psi),
207 respectively. Sixteen solenoid valves (LHLA1221111H, the Lee Company, Westbrook, CT) were
208 employed to switch between pressure, vacuum, and atmospheric pressure. Below the heating plate
209 was the optical detection module. An optical box driven by a stepping motor scanned the
210 amplification chambers of the chips through the ITO glasses. A 365-nm exciting beam from a LED
211 (CREE 3535, Epileds, Taiwan) first passed through a filter (et365/10x, Chroma, Brattleboro, VT), was
212 then reflected by a dichroic beam splitter (t455lpxt, Chroma), and focused in the chamber by a convex

213 lens (GCL-0101, Daheng Optics, Beijing, China). The excited fluorescence signal passed through the
214 dichroic beam splitter and a filter (zet514/10x, Chroma) installed before a PMT (photomultiplier
215 tubes, H9307, Hamamatsu, Shizuoka Japan). A Raspberry Pi board (3B, Digi-Key, Taiwan) combined
216 with a custom-build circuit board was developed for signal processing and controlling.

217 2.4. DNA extraction and LAMP reaction


218 Bacteriophage λ -DNA (Promega, Madison, WI) was employed to examine the DNA capture
219 efficiency of the iLAMP microdevice. After on-chip capture of λ -DNA, the chitosan-modified filter
220 paper was taken out and placed into tubes for real-time PCR on a Bio-Rad iQ5 system (Bio-Rad,
221 Hercules, CA). In each tube, a 25- μ L mixture was composed of 0.5 μ L of forward/reverse primer
222 (listed in Table S1), 12.5 μ L of Power 2 \times SYBR real-time PCR premix (Thermo Fisher), 11.5 μ L of DI
223 water, and the filter paper. The thermal cycling protocol included an initial activation of Taq
224 polymerases at 95 $^{\circ}$ C for 5 min, followed by 35 cycles of 95 $^{\circ}$ C for 30 s, 60 $^{\circ}$ C for 30 s, and 72 $^{\circ}$ C for 30
225 s, and a final extension step for 10 min at 72 $^{\circ}$ C.

226 The detection of *Chlamydia trachomatis* (CT) was realized by amplifying a specific sequence in its
227 7.5 kb cryptic plasmid. Each CT has 7~10 copies of this plasmid and the sequences of the template
228 and LAMP primers are listed in Table S1. Swab samples were prepared as follows: one-microliter
229 inactivated CT particles obtained from the CT Nucleic Acid Testing Kit (DAAN Gene, Guangzhou,
230 China) was pipetted onto a urethral swab. After air-dried, the swab tip was cut off and inserted into
231 the device for the on-chip analysis. Since 250 μ L of lysis buffer was employed to flush the swab, a
232 total of 2500, 250, and 25 CT particles on the swabs can theoretically generate the lysates with
233 concentrations of 10, 1, and 0.1 CT particles/ μ L, respectively. A 25- μ L LAMP mixture contained 1.6
234 μ M each of the inner primer (FIP and BIP), 0.2 μ M each of the outer primer (F3 and B3), 0.4 μ M of
235 the loop primer (LF), 1 \times Isothermal Amplification Buffer (20 mM tris-HCl, 10 mM (NH₄)₂SO₄, 50 mM
236 KCl, 2 mM MgSO₄, 0.1% Tween[®] 20, pH 8.8@25 $^{\circ}$ C, NEB, Ipswich, MA), 6.0 mM of MgSO₄, 1.4 mM of
237 dNTPs (Sangon Biotech, Shanghai, China), 0.5 M of betaine (Sigma-Aldrich), 0.15 mM of calcein
238 (Coolaber, Beijing, China), 0.5 mM of MnCl₂ (Tiandz, Beijing, China), 8 units of Bst 2.0 WarmStart[®]
239 DNA Polymerase (NEB), 6 μ M Bovine serum albumin (BSA) (Sigma-Aldrich), and the template. The
240 entire operation of the microdevice was performed automatically on a home-made instrument. The
241 LAMP amplification graphs were plotted and outputted by the embedded system of the instrument,
242 which also reported the threshold time based on predefined calibration curves.

243 3. Results and discussion

244 3.1. Unit operations of the microfluidic platform

245 A microfluidic platform is usually required to provide a set of validated unit operations for fluid
246 handlings, which can be combined and thereby realize application-specific assays on the platform. In
247 our system, the aforementioned basic elements were used to design and construct a series of unit
248 operations. First, multiple prestored reagents are often sequentially loaded into the chip for
249 downstream analysis. A sequential pressure injector was designed to accomplish this operation by
250 linearly linking multiple check valves (in) (v1-v4) as illustrated in Figure 2A. Due to the one-way-
251 flow property of these check valves, the reagents can be sequentially loaded into the chip by simply
252 applying pressures to the valves one by one without the worry of mistakenly mixing reagents in the
253 other compartments (Figure 2B and Video S1). In the end of this structure, a check valve (out) (v5) is
254 employed as a waste reservoir to collect all the reagents from the chip. Second, during liquid
255 transports, the fluid valving is often needed to control the flow path. As shown in Figure 2C, the
256 fluidic valving can be easily achieved by adding an on-off valve (v2) between two check valves (v1
257 and v3). As shown in Figure 2D, for every P_v, there is a critical P_o on the red fitted line that can burst
258 out the valve. As a result, we need to make sure the working parameters are always below the red
259 line to keep the valve close. To open the valve, a vacuum can be simply applied to the valve. The air
260 pump we used in the instrument can provide a maximum P_o of 59 kPa, which was sufficient to seal
261 the amplification chamber during LAMP (Figure S3).



262


263 **Figure 2.** Unit operations of the microfluidic platform. The illustration (A) and validation (B) of the
 264 sequential pressure injector. The illustration (C) and quantification (D) of the channel on/off control
 265 (mean \pm SD, $n = 3$). (E) The macro-mixer. (F) Different operations based on the macro-mixer:
 266 reagent stirring, powder dissolving, and swab flushing.

267 Fluid mixing is another indispensable unit operation for a microfluidic platform. Here we
 268 designed a macro-mixer containing two check valves (in) (v1 and v2), a double-check valve (v3), and
 269 a check valve (out) (v4). As illustrated in Figure 2E, the reagents stored in v1 and v2 are sequentially
 270 loaded into the v3 compartment, in which the reagents are mixed thoroughly by continuously
 271 bubbling. After that, the mixture is driven to v4 for the downstream analysis. We found this bubbling
 272 action could efficiently mix two reagents in less than 1 min. This structure can be easily modified to
 273 fit many unit operations that are often encountered in clinical diagnosis. As shown in Figure 2F, air
 274 can be blown into the compartment of the double-check valve, in which the floating bubbles disturb
 275 the liquid quickly to achieve the stirring effect. The same structure can also be used for dissolving
 276 freeze-dried powders: water is injected into the compartment to dissolve the powder freeze-dried
 277 in the compartment of the double check valve followed by the bubbling vortex. Another function that
 278 can be achieved by this structure is the swab flushing. A swab, which is a common sampling mean
 279 in clinic diagnosis, is inserted into the compartment directly. Then, water or other reagent is pressed
 280 into the compartment and thoroughly flush the swab by the bubbling vortex. All the unit operations
 281 described above form a “microfluidic component library” that can be assembled together to enable
 282 the design of any application-specific microfluidic system in a short turnaround time. This library
 283 can be expanded by incorporating more unit operations in the future.

284 3.2. Design process of a fully integrated system for pathogen detection

285 To illustrate how to design an integrated microdevice using the “3D extensible” paradigm, we
 286 developed a fully integrated microsystem for nucleic acid-based pathogen detection. *Chlamydia*
 287 *trachomatis* (CT), the leading cause of sexually transmitted diseases (STDs) [38], was chosen as the
 288 target to test this microsystem. The development process of a fully integrated microsystem for
 289 pathogen detection based on the “3D extensible” design paradigm started with the determination of
 290 the biochemical assay that should be validated with the conventional off-chip operations in the first
 291 place. In the current study, first, *Chlamydia trachomatis* is usually sampled by urethral or vaginal
 292 swabs in clinical diagnosis. A thorough rinse of the sample swab in a lysis buffer could effectively
 293 release and lyse cells from the swab tip to the solution. Second, a chitosan-modified glass filter paper
 294 previously developed by our group was employed for the DNA extraction [37]. This filter paper-

295 based method was chosen due to its over 90% DNA capture efficiency, the easy integration of a piece of filter
 296 of filter within a microstructure, and the most attractive feature- “*in situ*” PCR capability, with which
 297 all the DNA captured on the filter paper can be directly used for amplification without elution. In the
 298 off-chip format, the filter paper with captured DNA was directly thrown into an Eppendorf tube for
 299 amplification. Likewise, a single microreactor should work for both the DNA extraction and the
 300 amplification on the device. Third, the amplification and detection of the extraction DNA on the filter
 301 paper was achieved using the loop-mediated isothermal amplification (LAMP) coupled with calcein-
 302 based real-time fluorescence detection. While LAMP has a poor capability of quantitating starting
 303 templates compared with that of real-time PCR, its rapid reaction, high sensitivity, and low
 304 requirements for the control and detection match the need of developing a rapid screening method
 305 for sexually-transmitted *C. trachomatis* infections in clinical diagnosis.




306

307 **Figure 3.** Design of the iLAMP system. (A) The schematic diagram of the iLAMP microdevice. v1~v9
 308 represent the valve structures from the basic elements. c1 is the chamber on the chip. Volumes of each
 309 valve compartment and chamber are listed above corresponding structures. (B) The iLAMP device is
 310 comprised of a block, a piece of DS tape, and a chip covered with adhesive PCR foil. Reagents are
 311 prestored in valve compartments. (C) Photographs of the iLAMP device and the reaction chamber. A
 312 piece of chitosan-modified filter paper is embedded in the chamber for DNA capture and “*in situ*”
 313 LAMP. (D) Photograph of the control and detection instrument of the iLAMP device.

314 After the entire biochemical assay was finalized and validated, a schematic diagram was drawn
 315 using the unit operations and basic elements as building blocks to design a fully integrated LAMP
 316 (iLAMP) device that essentially replicated the entire procedure of the off-chip assay. As shown in
 317 Figure 3A, a unit operation of swab flushing (v1 and v2) was connected to a sequential pressure
 318 injector for DNA extraction and amplification. A powder dissolving unit (v5 and v6) was inserted
 319 into the design for dissolving lyophilized LAMP reagents with enzymes. A chamber (c1) with the
 320 embedded filter paper was employed as the reaction “tube”. Owing to the use of the chitosan-
 321 modified filter paper, both DNA capture and amplification were performed in this single chamber.
 322 Two on-off valves (v7 and v8) were employed to seal the chamber during amplification. Finally, a
 323 check valve (out) (v9) was designed in the end of the device to collect all the wastes driven through
 324 the chamber. Based on the device schematic, a microfluidic device can be further finalized and
 325 constructed by applying the rules of the “3D extensible” design paradigm. As illustrated in Figure
 326 3B, this slim, cassette-like device consists of three major components: a 3D block containing
 327 compartments, a piece of DS tape, and a 2D chip. Three key issues need to be determined in the

328 process from the schematic to the device: i) the sizes of all the compartments in the block need to be
 329 determined according to the reagent volumes and the functions that are used in the assay; ii) the
 330 pattern on the DS tape should be designed based on the types of the valves connected to the
 331 compartments; iii) the microstructures on the upper side of the chip should be finalized based on the
 332 bottom horizontal lines in the schematic. In addition, a piece of chitosan-modified filter paper was
 333 embedded in the end of the chamber (c1) to enable DNA capture (Figure 3C). A piece of patterned
 334 non-transparent adhesive PCR plate foil was attached onto the upper side of the chip before bonding,
 335 providing a uniform fluorescence background for detection and a biocompatible surface for more
 336 efficient amplification. The cassette-like iLAMP microdevice has dimensions of $76.5 \times 10 \times 32$ mm and
 337 the detailed design can be found in Figure S4. The microdevice was operated on the home-made
 338 instrument which was developed according to the needs of the assay (Figure 3D). Up to eight
 339 microdevices could be loaded on the instrument side by side in an array and the number of the
 340 devices can be flexibly adjusted according to the need of each run.

341 3.3. Operation of the iLAMP microsystem



342


343 **Figure 4.** Operation of the iLAMP microsystem. The total analytical time was about 82 min, including
 344 22 min for DNA extraction and 60 min for LAMP.

345 As demonstrated in Figure 4 and Video S2, after the swab insertion and the device loading, the
 346 rest of the procedure of the *C. trachomatis* detection could be automatically conducted under the
 347 control of the instrument without any manual interventions. Briefly, the swab tip was first inserted
 348 into the sample compartment (v2) of the device which was then sealed by the connection manifold
 349 on the instrument. Lysis buffer (v1) was injected into the swab compartment and air was
 350 continuously blown for 15 minutes to flush the swab by the bubbling vortex. The lysate was then
 351 driven through the chamber (c1) containing the filter paper, by which DNA was captured. Then, the
 352 washing buffer (v3) and the TE solution (v4) were sequentially injected through the paper to remove
 353 the residual lysis buffer and to neutralize the pH in the chamber. The LAMP mix (v6), which was
 354 dissolved by adding DI water (v5), was injected slowly to fill the reaction chamber without
 355 introducing any air bubbles. Finally, the valves (v7 and v8) at the both ends of the chamber were
 356 closed and the chamber was heated by the ITO heater underneath the device. Temperature calibration
 357 showed that the chamber was heated to $65\text{ }^{\circ}\text{C}$ in 5 min and maintained for 60 min (Figure S5). Real-
 358 time fluorescence signals were recorded by the scanning PMT in the detection instrument.

359 3.4. Evaluation of analytical steps

360 The DNA capture by the chitosan-modified filter paper was first verified on the device.
 361 Previously, we had proved this filter paper could provide a high DNA capture efficiency [37,39].
 362 However, in the current system, since this filter was embedded into the chamber in a lateral flow
 363 format, its performance should be carefully optimized and tested. First, different amounts of λ -DNA
 364 prepared in 1-mL MES (2-(N-morpholino) ethanesulfonic acid) solution (pH=5.0) were injected into
 365 the chamber at a flow rate of 1 mL/min using a syringe pump, followed by washes with 50- μL 1%
 366 SDS and 200- μL 1 \times TE buffer. After that, the filter paper was taken out from the chip and transferred
 367 into a PCR tube for real-time PCR quantitation of captured DNA on the filter. Figure 5A illustrated
 368 that the capture efficiencies were kept above 96% when the input DNA was in the range of 5-20 ng,

369 and the efficiencies declined gradually with the input amounts increased to 25 and 50 ng due to the
 370 saturation of the filter paper. Therefore, we estimated the DNA capture capacity of our system is in
 371 the range of 20 to 25 ng. When the template amount was further reduced to 10,000, 1000, and even
 372 100 copies of λ -DNA diluted in 1-mL MES, the average capture efficiencies were still higher than 96%
 373 (Figure 5B). Such an extraordinary capture efficiency with highly diluted DNA resulted from the
 374 sufficient interactions between DNA and the filter paper in the lateral flow mode. After the
 375 verification of the on-chip DNA capture, we next tested the on-chip isothermal amplification and
 376 detection of a specific sequence in the cryptic plasmid of *Chlamydia trachomatis*. A series of 15- μ L
 377 LAMP mixtures, containing 10^2 , 10^3 , 10^4 , and 10^6 copies of template along with DI water as negative
 378 controls, were injected into the chambers for LAMP tests at 65 °C for 60 minutes. The typical real-
 379 time fluorescence graphs were shown in Figure 5C and the average threshold time (Tt) calculated
 380 from three repeats (Figure S6) was plotted as a function of the log of the template copy number in
 381 Figure 5D. The linear fit with an R^2 of 0.994 confirmed the reliable LAMP reactions and the
 382 fluorescence detections on the device.




383

384 **Figure 5.** Characterization and evaluation of the iLAMP system. Evaluation of DNA capture by the
 385 chitosan-modified filter paper in the iLAMP device using λ -DNA samples. (A) The average DNA
 386 capture efficiencies were above 96% when input was between 5~20 ng (mean \pm SD, $n = 3$). (B) The
 387 average capture efficiencies were above 96% when 10,000, 1000 or even 100 copies of λ -DNA were
 388 diluted in 1-mL MES (mean \pm SD, $n = 3$). (C) Validation of on-chip amplifications of 0, 10^2 , 10^3 , 10^4 , and
 389 10^6 copies of templates. The experiments were repeated three times and only one set of results were
 390 shown here. (D) The fitted curve between the log of the template copy number and the threshold time
 391 (Tt) in the fluorescence graphs (mean \pm SD, $R^2 = 0.994$, $n = 3$).

392 3.5. "Sample-in-answer-out" analyses in the iLAMP system

393 Following the verification of each analytical step independently, the entire assay was tested on
 394 the device to prove the "sample-in-answer-out" capability of the iLAMP system. Swabs containing
 395 2500, 250, and 25 CT particles were employed as the mock clinical samples. At each concentration,
 396 five microdevices were loaded onto the instrument and tested simultaneously by following the
 397 procedure described above. The real-time fluorescence graphs at the concentrations of 10 and 1 CT/ μ L
 398 demonstrated steep rises of the baseline fluorescence signals, indicating the successful amplifications
 399 of the target sequences of the CT particles (Figure 6A). By contrast, the steep rises of the signals were
 400 either delayed or disappeared at the concentration of 0.1 CT/ μ L, suggesting that the system had
 401 reached its limit of detection (LOD). The threshold times extracted from these graphs were also
 402 plotted as a function of the concentration of CT particles. Figure 6B showed that a negative correlation
 403 was established between the sample concentration and the Tt. The LOD of our system was

404 determined to be 1 CT particles/ μL , which was 10 times higher than that of the commercial kit
 405 (DAAN Gene, 10 CT particles/ μL).



406

407 **Figure 6.** “Sample-in-answer-out” analyses of mock clinical samples using the iLAMP system. (A)
 408 Swab samples producing 10, 1, and 0.1 CT particles/ μL in the lysis buffer tested on the iLAMP
 409 microsystem. In each group, five microdevices were operated simultaneously on the instrument. Only
 410 3 in 5 tests successfully amplified the targets in the 0.1 CT/ μL group, indicating the system had
 411 reached its limit of detection. (B) The boxplot between the input numbers of CT particles and the
 412 amplification threshold times in the “sample-in-answer-out” analyses ($n = 5$).

413 The iLAMP system proved the excellent design capability of the “3D extensible” paradigm.
 414 Along the length direction of the microdevice, the functions were realized by linking a series of
 415 proved unit operations from the “microfluidic component library”, and the same method can be
 416 applied to develop more IVD microsystems after further improvements including reagents mixing
 417 and quantification. The extensibility in the height direction of the block provided the capacity for
 418 swab handling and reagents storage, thereby making a fully integrated and fully enclosed
 419 microdevice for “sample-in-answer-out” pathogen detection. This cassette-like microdevice can be
 420 arrayed along its width direction to achieve an adjustable throughput on a control and detection
 421 instrument. The high sensitivity proved by repeated experiments could be mainly attributed to the
 422 enrichment of nucleic acid by the filter paper and the “*in situ*” amplification. In future, the mass
 423 production of the microdevice could be realized by plastic injection molding coupled with the
 424 convenient tape bonding, providing a powerful and cost efficient alternative for pathogen detection
 425 in IVD market.

426 4. Conclusions

427 Our “3D extensible” design paradigm is a universal microfluidic platform specially developed
 428 for the use in clinical diagnosis. As the proofs of concepts, here we successfully developed an iLAMP
 429 system for pathogen detection. The iLAMP system possessed an excellent “world-to-chip” interface
 430 with the capability of directly processing a swab, a compact integration for the “sample-in-answer-
 431 out” operations, and an adjustable throughput to meet the uncertainty in the practical application.
 432 Our study clearly demonstrated the central role that the “3D extensible” design paradigm may play
 433 in the development of microfluidic systems for IVD. In addition, although we focused our efforts to
 434 the nucleic acid testing in the current study due to the complexity of the NATs, we believe other types
 435 of clinical diagnosis, such as immunoassays, can all be realized using the “3D extensible” design

436 method. We admit that our design paradigm still requires further development, such as the mass
437 production and the microfluidic component library. Nevertheless, our study successfully provides a
438 universal design paradigm that researchers can adopt to quickly develop integrated microsystems
439 for various IVD assays in the future.

440 **Supplementary Materials:** The following are available online at www.mdpi.com/xxx/s1, Table S1: Primers and
441 ordered sequences, Figure S1: Patterning procedure of the tape, Figure S2: Core structure of the iLAMP
442 instrument, Figure S3: Quantitative characterization of the pneumatic microvalves, Figure S4: Drawings of the
443 iLAMP microdevice, Figure S5: Temperature calibration of the iLAMP instrument, Figure S6: Validation of on-
444 chip amplification, Video S1: The demo of unit operations, Video S2: The working process of the iLAMP
445 microdevice.

446 **Author Contributions:** Z.G. conducted the experiments and helped write the manuscript; Y.G. and S.L. prepared
447 the chitosan-modified glass filter paper; B.L. helped construct the instrument; P.L. designed the entire study and
448 wrote the manuscript.

449 **Acknowledgments:** Financial support was provided by the National Key Research and Development Program
450 of China (No. 2016YFC0800703) from the Ministry of Science and Technology of China.

451 **Conflicts of interest:** There are no conflicts to declare.

452 References

- 453 1. Whitesides, G.M. The origins and the future of microfluidics. *Nature* **2006**, *442*, 368-373,
454 doi:10.1038/nature05058.
- 455 2. Sackmann, E.K.; Fulton, A.L.; Beebe, D.J. The present and future role of microfluidics in biomedical research.
456 *Nature* **2014**, *507*, 181-189, doi:10.1038/nature13118.
- 457 3. Yeo, L.Y.; Chang, H.C.; Chan, P.P.; Friend, J.R. Microfluidic devices for bioapplications. *Small* **2011**, *7*, 12-
458 48, doi:10.1002/sml.201000946.
- 459 4. Nayak, S.; Blumenfeld, N.R.; Laksanasopin, T.; Sia, S.K. Point-of-Care Diagnostics: Recent Developments
460 in a Connected Age. *Anal. Chem.* **2017**, *89*, 102-123, doi:10.1021/acs.analchem.6b04630.
- 461 5. LI, P. Microfluidics For IVD: In Pursuit Of The Holy Grail. *J. Bioeng. Biomed. Sci.* **2013**, *03*, doi:10.4172/2155-
462 9538.S8-e001.
- 463 6. Chin, C.D.; Linder, V.; Sia, S.K. Commercialization of microfluidic point-of-care diagnostic devices. *Lab*
464 *Chip* **2012**, *12*, 2118-2134, doi:10.1039/c2lc21204h.
- 465 7. Ahn, C.H.; Choi, J.W.; Beaucage, G.; Nevin, J.; Lee, J.B.; Puntambekar, A.; Lee, R.J.Y. Disposable Smart Lab
466 on a Chip for Point-of-Care Clinical Diagnostics. *Proc. IEEE* **2004**, *92*, 154-173, doi:10.1109/jproc.2003.820548.
- 467 8. Bhargava, K.C.; Thompson, B.; Malmstadt, N. Discrete elements for 3D microfluidics. *Proc. Natl. Acad. Sci.*
468 *U.S.A.* **2014**, *111*, 15013-15018, doi:10.1073/pnas.1414764111.
- 469 9. Haeberle, S.; Zengerle, R. Microfluidic platforms for lab-on-a-chip applications. *Lab Chip* **2007**, *7*, 1094-1110,
470 doi:10.1039/b706364b.
- 471 10. Mark, D.; Haeberle, S.; Roth, G.; von Stetten, F.; Zengerle, R. Microfluidic lab-on-a-chip platforms:
472 requirements, characteristics and applications. *Chem. Soc. Rev.* **2010**, *39*, 1153-1182, doi:10.1039/b820557b.
- 473 11. Strohmeier, O.; Keller, M.; Schwemmer, F.; Zehnle, S.; Mark, D.; von Stetten, F.; Zengerle, R.; Paust, N.
474 Centrifugal microfluidic platforms: advanced unit operations and applications. *Chem. Soc. Rev.* **2015**, *44*,
475 6187-6229, doi:10.1039/c4cs00371c.
- 476 12. Martinez, A.W.; Phillips, S.T.; Whitesides, G.M.; Carrilho, E. Diagnostics for the developing world:
477 microfluidic paper-based analytical devices. *Anal. Chem.* **2010**, *82*, 3-10, doi:10.1021/ac9013989.
- 478 13. Yetisen, A.K.; Akram, M.S.; Lowe, C.R. Paper-based microfluidic point-of-care diagnostic devices. *Lab Chip*
479 **2013**, *13*, 2210-2251, doi:10.1039/c3lc50169h.
- 480 14. Yang, H.; Chen, Z.; Cao, X.; Li, Z.; Stavrakis, S.; Choo, J.; deMello, A.J.; Howes, P.D.; He, N. A sample-in-
481 digital-answer-out system for rapid detection and quantitation of infectious pathogens in bodily fluids.
482 *Anal. Bioanal. Chem.* **2018**, *410*, 7019-7030, doi:10.1007/s00216-018-1335-9.
- 483 15. Easley, C.J.; Karlinsey, J.M.; Bienvenue, J.M.; Legendre, L.A.; Roper, M.G.; Feldman, S.H.; Hughes, M.A.;
484 Hewlett, E.L.; Merkel, T.J.; Ferrance, J.P., et al. A fully integrated microfluidic genetic analysis system with
485 sample-in-answer-out capability. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 19272-19277,
486 doi:10.1073/pnas.0604663103.

- 487 16. Gorkin, R.; Park, J.; Siegrist, J.; Amasia, M.; Lee, B.S.; Park, J.M.; Kim, J.; Kim, H.; Madou, M.; Cho, Y.K.
488 Centrifugal microfluidics for biomedical applications. *Lab Chip* **2010**, *10*, 1758-1773, doi:10.1039/b924109d.
- 489 17. Snyder, J.L.; Getpreecharsawas, J.; Fang, D.Z.; Gaborski, T.R.; Striemer, C.C.; Fauchet, P.M.; Borkholder,
490 D.A.; McGrath, J.L. High-performance, low-voltage electroosmotic pumps with molecularly thin silicon
491 nanomembranes. *Proc. Natl. Acad. Sci. U.S.A.* **2013**, *110*, 18425-18430, doi:10.1073/pnas.1308109110.
- 492 18. Abdelgawad, M.; Wheeler, A.R. The Digital Revolution: A New Paradigm for Microfluidics. *Adv. Mater.*
493 **2009**, *21*, 920-925, doi:10.1002/adma.200802244.
- 494 19. Voiculescu, I.; Nordin, A.N. Acoustic wave based MEMS devices for biosensing applications. *Biosens.*
495 *Bioelectron.* **2012**, *33*, 1-9, doi:10.1016/j.bios.2011.12.041.
- 496 20. Kim, J.; Johnson, M.; Hill, P.; Gale, B.K. Microfluidic sample preparation: cell lysis and nucleic acid
497 purification. *Integr. Biol.* **2009**, *1*, 574-586, doi:10.1039/b905844c.
- 498 21. Parida, M.M.; Santhosh, S.R.; Dash, P.K.; Tripathi, N.K.; Saxena, P.; Ambuj, S.; Sahni, A.K.; Lakshmana-Rao,
499 P.V.; Morita, K. Development and evaluation of reverse transcription-loop-mediated isothermal
500 amplification assay for rapid and real-time detection of Japanese encephalitis virus. *J. Clin. Microbiol.* **2006**,
501 *44*, 4172-4178, doi:10.1128/JCM.01487-06.
- 502 22. Campos, C.D.M.; Gamage, S.S.T.; Jackson, J.M.; Witek, M.A.; Park, D.S.; Murphy, M.C.; Godwin, A.K.;
503 Soper, S.A. Microfluidic-based solid phase extraction of cell free DNA. *Lab Chip* **2018**, *18*, 3459-3470,
504 doi:10.1039/c8lc00716k.
- 505 23. Xu, G.; Hsieh, T.M.; Lee, D.Y.; Ali, E.M.; Xie, H.; Looi, X.L.; Koay, E.S.; Li, M.H.; Ying, J.Y. A self-contained
506 all-in-one cartridge for sample preparation and real-time PCR in rapid influenza diagnosis. *Lab Chip* **2010**,
507 *10*, 3103-3111, doi:10.1039/c005265e.
- 508 24. Nguyen, H.V.; Nguyen, V.D.; Lee, E.Y.; Seo, T.S. Point-of-care genetic analysis for multiplex pathogenic
509 bacteria on a fully integrated centrifugal microdevice with a large-volume sample. *Biosens. Bioelectron.* **2019**,
510 *136*, 132-139, doi:10.1016/j.bios.2019.04.035.
- 511 25. Hoffmann, J.; Mark, D.; Lutz, S.; Zengerle, R.; von Stetten, F. Pre-storage of liquid reagents in glass
512 ampoules for DNA extraction on a fully integrated lab-on-a-chip cartridge. *Lab Chip* **2010**, *10*, 1480-1484,
513 doi:10.1039/b926139g.
- 514 26. Ferguson, B.S.; Buchsbaum, S.F.; Wu, T.T.; Hsieh, K.; Xiao, Y.; Sun, R.; Soh, H.T. Genetic analysis of H1N1
515 influenza virus from throat swab samples in a microfluidic system for point-of-care diagnostics. *J. Am. Chem.*
516 *Soc.* **2011**, *133*, 9129-9135, doi:10.1021/ja203981w.
- 517 27. Sun, Y.; Haglund, T.A.; Rogers, A.J.; Ghanim, A.F.; Sethu, P. Review: Microfluidics technologies for blood-
518 based cancer liquid biopsies. *Anal. Chim. Acta* **2018**, *1012*, 10-29, doi:10.1016/j.aca.2017.12.050.
- 519 28. Culbertson, C.T.; Mickleburgh, T.G.; Stewart-James, S.A.; Sellens, K.A.; Pressnall, M. Micro total analysis
520 systems: fundamental advances and biological applications. *Anal. Chem.* **2014**, *86*, 95-118,
521 doi:10.1021/ac403688g.
- 522 29. Hsieh, Y.-F.; Yang, A.-S.; Chen, J.-W.; Liao, S.-K.; Su, T.-W.; Yeh, S.-H.; Chen, P.-J.; Chen, P.-H. A Lego®-like
523 swappable fluidic module for bio-chem applications. *Sens. Actuators, B* **2014**, *204*, 489-496,
524 doi:10.1016/j.snb.2014.07.122.
- 525 30. Vittayarukskul, K.; Lee, A.P. A truly Lego (R)-like modular microfluidics platform. *J. Micromech. Microeng.*
526 **2017**, *27*, doi:10.1088/1361-6439/aa53ed %/ IOP PUBLISHING LTD.
- 527 31. Meng, Z.-J.; Wang, W.; Liang, X.; Zheng, W.-C.; Deng, N.-N.; Xie, R.; Ju, X.-J.; Liu, Z.; Chu, L.-Y. Plug-n-play
528 microfluidic systems from flexible assembly of glass-based flow-control modules. *Lab Chip* **2015**, *15*, 1869-
529 1878, doi:10.1039/c5lc00132c.
- 530 32. Yuen, P.K. A reconfigurable stick-n-play modular microfluidic system using magnetic interconnects. *Lab*
531 *Chip* **2016**, *16*, 3700-3707, doi:10.1039/c6lc00741d.
- 532 33. Wang, R.; Zhao, R.; Li, Y.; Kong, W.; Guo, X.; Yang, Y.; Wu, F.; Liu, W.; Song, H.; Hao, R. Rapid detection of
533 multiple respiratory viruses based on microfluidic isothermal amplification and a real-time colorimetric
534 method. *Lab Chip* **2018**, *18*, 3507-3515, doi:10.1039/c8lc00841h.
- 535 34. Phaneuf, C.R.; Mangadu, B.; Tran, H.M.; Light, Y.K.; Sinha, A.; Charbonier, F.W.; Eckles, T.P.; Singh, A.K.;
536 Koh, C.Y. Integrated LAMP and immunoassay platform for diarrheal disease detection. *Biosens. Bioelectron.*
537 **2018**, *120*, 93-101, doi:10.1016/j.bios.2018.08.005.
- 538 35. Zhang, W.; Lin, S.; Wang, C.; Hu, J.; Li, C.; Zhuang, Z.; Zhou, Y.; Mathies, R.A.; Yang, C.J. PMMA/PDMS
539 valves and pumps for disposable microfluidics. *Lab Chip* **2009**, *9*, 3088-3094, doi:10.1039/b907254c.
- 540 36. Ogilvie, I.R.; Sieben, V.J.; Cortese, B.; Mowlem, M.C.; Morgan, H. Chemically resistant microfluidic valves

- 541 from Viton(R) membranes bonded to COC and PMMA. *Lab Chip* **2011**, *11*, 2455-2459, doi:10.1039/c1lc20069k.
- 542 37. Gan, W.; Gu, Y.; Han, J.; Li, C.X.; Sun, J.; Liu, P. Chitosan-Modified Filter Paper for Nucleic Acid Extraction
543 and "in Situ PCR" on a Thermoplastic Microchip. *Anal. Chem.* **2017**, *89*, 3568-3575,
544 doi:10.1021/acs.analchem.6b04882.
- 545 38. Meyer, T. Diagnostic Procedures to Detect Chlamydia trachomatis Infections. *Microorganisms* **2016**, *4*, 25,
546 doi:10.3390/microorganisms4030025.
- 547 39. Hui, J.; Gu, Y.; Zhu, Y.; Chen, Y.; Guo, S.J.; Tao, S.C.; Zhang, Y.; Liu, P. Multiplex sample-to-answer detection
548 of bacteria using a pipette-actuated capillary array comb with integrated DNA extraction, isothermal
549 amplification, and smartphone detection. *Lab Chip* **2018**, *18*, 2854-2864, doi:10.1039/c8lc00543e.